Incyte Corporation: Ovarian Neoplasms trials

The registry lists 12 Ovarian Neoplasms studies with Incyte Corporation as lead sponsor. 3 are open to participants now and 6 have results posted.

Phase 1 8Phase 2 8Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1Not yet recruitingNCT07797283Phase 3
• Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionRecruitingNCT07214779Phase 3
• A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionRecruitingNCT07023627Phase 2
• A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsTerminatedNCT05949632Phase 1/2Results posted
• A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid TumorsCompletedNCT03314935Phase 1/2Results posted
• Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results posted
• A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT02923349Phase 1/2Results posted
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedNCT02711137Phase 1/2Results posted
• A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)CompletedNCT02327078Phase 1/2Results posted
• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsCompletedNCT04580485Phase 1
• An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesTerminatedNCT03144661Phase 1
• A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line ChemotherapyTerminatedNCT01685255Phase 2